Clinical Trial Update: Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial of cilengitide in adults undergoing surgery for recurrent or progressive glioblastoma multiforme was terminated and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Gliosarcoma

Drugs mentioned

• cilengitide (cilengitide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2017-06-14